Halozyme Therapeutics Management

Management criteria checks 1/4

Halozyme Therapeutics' CEO is Helen Torley, appointed in Jan 2014, has a tenure of 9.92 years. total yearly compensation is $9.70M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth MX$419.22M. The average tenure of the management team and the board of directors is 1.9 years and 9.9 years respectively.

Key information

Helen Torley

Chief executive officer

US$9.7m

Total compensation

CEO salary percentage	9.0%
CEO tenure	9.9yrs
CEO ownership	0.5%
Management average tenure	1.9yrs
Board average tenure	9.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Helen Torley's remuneration changed compared to Halozyme Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	US$254m
Jun 30 2023	n/a	n/a	US$234m
Mar 31 2023	n/a	n/a	US$182m
Dec 31 2022	US$10m	US$872k	US$202m
Sep 30 2022	n/a	n/a	US$211m
Jun 30 2022	n/a	n/a	US$366m
Mar 31 2022	n/a	n/a	US$435m
Dec 31 2021	US$7m	US$830k	US$403m
Sep 30 2021	n/a	n/a	US$409m
Jun 30 2021	n/a	n/a	US$229m
Mar 31 2021	n/a	n/a	US$163m
Dec 31 2020	US$7m	US$791k	US$129m
Sep 30 2020	n/a	n/a	US$22m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$6m	US$761k	-US$72m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$51m
Dec 31 2018	US$6m	US$725k	-US$80m
Sep 30 2018	n/a	n/a	US$46m
Jun 30 2018	n/a	n/a	US$76m
Mar 31 2018	n/a	n/a	US$68m
Dec 31 2017	US$5m	US$671k	US$63m
Sep 30 2017	n/a	n/a	-US$88m
Jun 30 2017	n/a	n/a	-US$120m
Mar 31 2017	n/a	n/a	-US$116m
Dec 31 2016	US$5m	US$645k	-US$103m

Compensation vs Market: Helen's total compensation ($USD9.70M) is above average for companies of similar size in the MX market ($USD2.79M).

Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.

CEO

Helen Torley (60 yo)

9.9yrs

Tenure

US$9,696,978

Compensation

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Helen Torley	President	9.9yrs	US$9.70m	0.47% $ 419.2m
Nicole LaBrosse	Senior VP & CFO	1.8yrs	US$2.73m	0.0069% $ 6.1m
Michael LaBarre	Senior VP & Chief Technical Officer	no data	US$3.12m	0.12% $ 102.1m
Mark Snyder	Chief Legal Officer	1.9yrs	US$3.74m	0.0036% $ 3.2m
Cortney Caudill	Chief Operations Officer	less than a year	no data	no data
Tram Bui	Head of Investor Relations & Corporate Communications	1.9yrs	no data	no data
Amy Fox	Chief Human Resources Officer	3.9yrs	no data	no data
Steve Knowles	Chief Medical Officer	3.8yrs	no data	no data
Christopher Bryant	Chief Manufacturing Officer & Head of Technical Operations	2.8yrs	no data	no data
Kristin Schwartzbauer	Head of Quality	no data	no data	no data
Gary Grote	Chief Commercial Officer	less than a year	no data	no data
Christopher Wahl	Chief Business Officer	less than a year	no data	no data

1.9yrs

Average Tenure

59.5yo

Average Age

Experienced Management: HALO *'s management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Helen Torley	President	9.9yrs	US$9.70m	0.47% $ 419.2m
Connie Matsui	Independent Director	17.4yrs	US$333.50k	0.14% $ 120.3m
Jeffrey Henderson	Independent Chair of the Board	8.3yrs	US$382.72k	0.030% $ 26.2m
Daniel Von Hoff	Member of the Scientific Advisory Board	19.3yrs	no data	no data
Jeffrey Bleil	Member of the Advisory Board	no data	no data	no data
Gregory Frost	Chairman of Scientific Advisory Board	9.9yrs	US$68.17k	no data
Gerhard Baumgartner	Member of Scientific Advisory Board	19.5yrs	no data	no data
James Daly	Independent Director	8.9yrs	US$316.76k	0.0094% $ 8.4m
Sue Bailey	Member of Scientific Advisory Board	18.4yrs	no data	no data
Matthew Posard	Independent Director	10.8yrs	US$325.04k	0.080% $ 70.7m
Jean-Pierre Bizzari	Independent Director	8.9yrs	US$315.04k	0.044% $ 39.5m
Bernadette Connaughton	Independent Director	5.3yrs	US$320.04k	0.024% $ 21.7m

9.9yrs

Average Tenure

65yo

Average Age

Experienced Board: HALO *'s board of directors are considered experienced (9.9 years average tenure).

Halozyme Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Insufficient new directors

Insufficient new directors

Independent Director recently sold Mex$17m worth of stock

Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors

Recent updates

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Insufficient new directors

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

Insufficient new directors

Independent Director recently sold Mex$17m worth of stock

Full year 2022 earnings released: EPS: US$1.48 (vs US$2.86 in FY 2021)

Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors

Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Independent Director recently sold Mex$34m worth of stock

CFO & Director recently sold Mex$5.2m worth of stock

Third quarter 2022 earnings released: EPS: US$0.45 (vs US$1.53 in 3Q 2021)

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022

Halozyme Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.64 in 2Q 2021)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2022

Halozyme Therapeutics, Inc. Announces Positive Results from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq with ENHANZE in Advanced Non-Small Cell Lung Cancer

Halozyme Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment for Testosterone Replacement Therapy

Insufficient new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age